Fate Therapeutics (FATE) Projected to Post Earnings on Monday

Fate Therapeutics (NASDAQ:FATE) is anticipated to release its earnings data before the market opens on Monday, February 24th. Analysts expect Fate Therapeutics to post earnings of ($0.44) per share and revenue of $1.51 million for the quarter.

Fate Therapeutics Trading Down 8.1 %

Shares of Fate Therapeutics stock opened at $1.42 on Friday. The company has a market capitalization of $161.72 million, a PE ratio of -0.86 and a beta of 2.02. Fate Therapeutics has a 12 month low of $1.04 and a 12 month high of $8.83. The stock’s fifty day simple moving average is $1.49 and its 200 day simple moving average is $2.54.

Analyst Ratings Changes

Several brokerages recently commented on FATE. Wedbush reaffirmed a “neutral” rating and set a $5.00 price objective on shares of Fate Therapeutics in a research note on Tuesday, November 12th. Bank of America raised Fate Therapeutics from an “underperform” rating to a “neutral” rating in a research note on Monday, November 18th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Fate Therapeutics in a research note on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $6.75.

Insider Activity

In related news, Director Redmile Group, Llc acquired 397,964 shares of the firm’s stock in a transaction dated Friday, December 20th. The stock was bought at an average price of $1.68 per share, for a total transaction of $668,579.52. Following the acquisition, the director now directly owns 12,884,277 shares of the company’s stock, valued at approximately $21,645,585.36. The trade was a 3.19 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 5.00% of the stock is owned by corporate insiders.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.